Loading organizations...
BD (Becton, Dickinson and Company) is a multinational medical technology company that manufactures medical devices, instrument systems, and laboratory reagents, based in Franklin Lakes, New Jersey. The publicly traded corporation supplies hospitals, clinics, and research laboratories with essential healthcare equipment, including its widely recognized Vacutainer blood collection tubes, diagnostic systems, and specialized analytics services. Operating as a public company under the ticker NYSE: BDX, the enterprise historically reported generating $3.42 billion in annual sales while maintaining a global workforce of approximately 24,000 employees across its international operations. In recent corporate restructuring efforts, the organization announced the strategic spin-off of its dedicated diabetes care business, which was officially completed in April 2022 to form the standalone public entity Embecta Corporation. The multinational medical technology firm was originally founded in 1897 by Maxwell Becton and Fairleigh S. Dickinson.
Key people at BD.
BD (Becton, Dickinson and Company) is a leading global medical technology company that manufactures and sells medical devices, instrument systems, reagents, and provides consulting and analytics services, advancing healthcare through improved medical discovery, diagnostics, and care delivery.[5][6][7][8] It operates primarily in three segments—BD Medical (including Medication Delivery Solutions, Medication Management Solutions, Pharmaceutical Systems, and Advanced Patient Monitoring), with products serving hospitals, labs, clinics, physicians, and pharmaceutical companies worldwide, generating revenue from technologies that address infections, medication management, and diagnostics.[3][4][5] In fiscal 2025, BD reported 3.9% organic revenue growth in its core "New BD" business post-upcoming divestitures, adjusted EPS growth of 9.6% to $14.40, and margin expansion driven by operational efficiencies, while maintaining strong free cash flow margins of 12.9% over five years and a safe 3.0x net-debt-to-EBITDA ratio.[3][4]
BD touches 90% of hospital patients annually through its products and invests heavily in R&D, with global manufacturing across North America, Europe, and Asia, positioning it as a Fortune 500 company (#211 in 2024) with resilient growth amid healthcare challenges.[2][3][5][6]
Founded over 125 years ago, BD (Becton, Dickinson and Company) has evolved from early medical device innovations into a multinational powerhouse in medtech.[6][8] Key historical milestones include the 2014 acquisition of CareFusion for $12.2 billion, expanding its medication management capabilities; the 2017 acquisition of C.R. Bard, rebranded under BD and bolstering vascular, urology, and oncology portfolios; and the 2024 purchase of Edwards Lifesciences' critical care unit for $4.2 billion, forming the Advanced Patient Monitoring business.[5]
The company's idea emerged from foundational healthcare needs, with early traction in syringes and diagnostics, leading to pivotal moments like these acquisitions that scaled its global reach to serve hundreds of countries and produce billions of devices annually.[6][7][8] Leadership under Chairman, CEO, and President Tom Polen has emphasized execution, as seen in fiscal 2025 results amid a transformative spin-off of its Biosciences and Diagnostic Solutions businesses.[4]
BD rides megatrends in medtech like aging populations, infection control, and precision diagnostics, amplified by post-pandemic healthcare digitization and supply chain resilience needs.[3][6][8] Timing is favorable amid value-unlocking deals like the Waters spin-off, which removes growth overhangs and funds $4B cash infusion, aligning with market forces favoring recession-resilient firms with absolute value in frothy markets.[2][4]
As a scale player influencing the ecosystem through acquisitions, R&D, and global supply (billions of devices yearly), BD shapes standards in medication management and monitoring, enabling providers to tackle infections and care delivery—though execution risks in M&A integration and new product development persist.[2][3][5]
BD's trajectory hinges on executing the Q1 2026 Waters spin-off, unlocking value in "New BD" at attractive valuations (<10x FY26 earnings) while sustaining 3-5% organic growth via franchises like PureWick™ and oncology tools.[2][4] Trends like AI-driven diagnostics, outpatient shifts, and volume-based pricing in regions like China will shape it, with strengths in cash generation supporting buybacks, R&D, and bolt-ons despite debt from deals.[2][3][4]
Influence may evolve toward a leaner medtech pure-play, prioritizing margins (targeted 25%+ adjusted operating) and downside protection, potentially delivering superior returns if catalysts like growth normalization materialize—cementing its role from good to great in advancing global health.[1][2][6]
BD has 3 tracked investments across 3 companies. The latest tracked deal is $6.0M Seed in 10 Minute School in October 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2023 | 10 Minute School | $6.0M Seed | Kirill Kozhevnikov | Andreessen Horowitz, LGF, MYASIAVC PTE LTD, Otherwise Fund, RTP Global, Akshay Kothari, Amit Gupta, Eric WU, Evan Moore, Julia Dewahl, Kunal Shah, Kunal Shah, Sajid Rahman, Peak XV Partners (Sequoia Capital India) |
| Feb 1, 2022 | Day Zero Diagnostics | $21.0M Series U | Sands Capital | Craft Ventures, Tiffany, Anne Wojcicki, Golden Seeds, Hongkou Capital, Panacea Venture, Triventures |
| Aug 1, 2017 | MedAware | $8.0M Series A | — | 500 Global, Catapult Capital, FJ Labs, Git1k, OurCrowd, Outlander Labs, Practical Venture Capital, Venture Highway, Gourav Bhattacharya, Gefen Capital, Yingcheng City Fubon Technology |
Key people at BD.
